➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Baxter
AstraZeneca
Merck
Moodys

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

Patent: 7,888,490

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,888,490
Title:Process for the preparation of non-toxic anthrax vaccine
Abstract: Anthrax toxin, comprising of protective antigen (PA), lethal factor (LF) and edema factor (EF) is a major virulent factor of B. anthracis. Protective antigen, PA is the main component of all the vaccines against anthrax. The protective efficacy of PA is greatly increased if small quantities of LF of EF are incorporated into the vaccines. An ideal vaccine against anthrax should contain PA, LF and EF together, but this combination would be toxic. Therefore, the biologically inactive mutant preparations of PA, LF and EF may be used together for better immunoprotection. The present invention describes the method for generation of recombinant vaccine against anthrax, comprising of non-toxic, mutant anthrax toxin proteins. The procedure involves site-directed mutagenesis of the native genes of the toxin proteins, the expression and purification of the mutant proteins and finally characterization of these proteins.
Inventor(s): Bhatnagar; Rakesh (New Delhi, IN), Gupta; Pankaj (New Delhi, IN), Batra; Smriti (New Delhi, IN), Chauhan; Vibha (New Delhi, IN), Singh; Aparna (New Delhi, IN), Ahuja; Nidhi (New Delhi, IN), Kumar; Praveen (New Delhi, IN)
Assignee: Centre of Biotechnology Jawaharlal Nehru University (New Delhi, IN)
Application Number:10/497,673
Patent Claims:see list of patent claims

Details for Patent 7,888,490

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Emergent Biodefense Operations Lansing, Llc BIOTHRAX bacillus anthracis INJECTION, SUSPENSION 103821 1 1970-11-04   Start Trial Centre of Biotechnology Jawaharlal Nehru University (New Delhi, IN) 2021-12-05 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
McKinsey
Mallinckrodt
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.